Opinion|Videos|February 28, 2026
Considerations for integrating immunotherapy into earlier stages of bladder cancer
Author(s)Kristen R. Scarpato, MD, MPH
Fact checked by: Hannah Clarke
Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer.
Advertisement
In the following video, Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer (NMIBC). Scarpato is an associate professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Alternative BCG strains may help address ongoing supply challenges in NMIBC
2
Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
5